What is the packaging standard?

Packing is done as per client's requirements.

Veterinary Feed Grade Supplement Bile Deoxycholic Cholic Acid Premix

Name: Veterinary Feed Grade Supplement Bile Deoxycholic Cholic Acid Premix
Brand: Shandong Ginye Biotech Co., Ltd.
SKU: 1968263242

Shandong, ChinaShandong Ginye Biotech Co., Ltd.

US$10.00

25 kg

Sample price:US$10.00/kg.Request sample

Product profile

Customization

Available

Certification

ISO

Shape

Powder

Model NO.

30%

Type

Bile Acid

Assay

30%

Content

Cholic Acid Deoxycholic Acid Other Deoxycholic Aci

OEM ODM

Yes

Standard

Function

Nutrition Enhancer

Transport Package

Drum

Specification

25kg

Trademark

GINYE

Origin

China

HS Code

2309901000

Production Capacity

2000 Kg / Day

Key features

Customizable Packaging: Packing is tailored to meet specific client requirements.

High Monthly Capacity: Production capacity reaches 5000kgs per month.

OEM/ODM Support: We support OEM and ODM customization services.

ISO Certified Quality: Product meets ISO certification standards.

Nutrition Enhancer: Functions as a nutrition enhancer for veterinary feed.

Precise Assay Content: Assay content is standardized at 30%.

CP Standard Compliance: Product adheres to CP (Chinese Pharmacopoeia) standards.

Fast Off-Season Delivery: Lead time is within 15 workdays during off-season.

Company profile

Shandong Ginye Biotech Co., Ltd.

Shandong, China

Business Type: Manufacturer/Factory, Trading CompanyExport Year: 2018-12-10Nearest Port: QINGDAOAverage Response Time: ≤3.30hTerms of Payment: LC, T/T, D/P, etc.International Commercial Terms(Incoterms): FOB, EXW, CFR, CIF, DDP

AI-Powered supplier vetting

SummaryShandong Ginye Biotech Co., Ltd. is a China-based private trading company and manufacturer focused on animal pharmaceuticals, feed additives, pet medicines, and related products. It reports ISO 9001 and GMP certification, two GMP factories, ten production lines in one description, six operating production lines in another, more than one hundred products, and dedicated R&D and quality-control personnel. The supplier began exporting in 2018, with exports representing 51%–70% of total sales, and reports cooperation with several animal-health research institutions. Evidence confirms production, certification, export activity, and research cooperation, but does not establish after-sales processes, customization services, audited financial strength, or a broad customer track record.

Supplier typeThe supplier is explicitly identified as both a trading company and manufacturer/factory. Its stated business includes research, production, and trading of animal pharmaceuticals, feed additives, and pet products, indicating an integrated supplier model rather than a pure intermediary.

CertificationsThe supplier reports ISO 9001 and GMP certification and states that it operates its quality management system according to GMP standards. These statements provide explicit evidence of formal quality-system and GMP compliance claims.

R&D capabilityThe supplier describes research and development as part of its core business and reports cooperation with Shandong Agricultural Academy, China Veterinary Herb Medicine Industry Research Institute, Shandong Herb Medicine University, and Shandong Agricultural University. It also states that it researches and commercializes recent research results, supporting an established innovation orientation.

Production capacityThe supplier reports two modern GMP factories, ten production lines in one description, six operating production lines in another, and more than one hundred products across multiple dosage forms. It also reports 11–20 quality-control staff and annual output data, providing explicit evidence of substantial manufacturing capacity, although the differing line counts should be clarified.

Client casesThe records show transaction or buyer associations involving Vietnam, Pakistan, and Bangladesh, including SHAH POULTRY INTERNATIONAL and CHEMBIO TECH LTD, and identify products such as CEFGIN-100 and a vitamin premix. These records demonstrate some cross-border commercial activity, but the limited number of transactions does not establish a broad or well-documented customer portfolio.